検索
Neumora Therapeutics Inc
NMRAウォッチリストに追加
1.610USD
-0.040-2.42%
終値 07-31 16:00（ET）15分遅れの株価
298.31M時価総額
損失額直近12ヶ月PER
詳細情報 Neumora Therapeutics Inc 企業名
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Neumora Therapeutics Incの企業情報
企業コードNMRA
会社名Neumora Therapeutics Inc
上場日Sep 15, 2023
最高経営責任者「CEO」Berns (Paul L)
従業員数110
証券種類Ordinary Share
決算期末Sep 15
本社所在地260 Arsenal Place, Suite 1
都市WATERTOWN
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02472
電話番号18577600900
ウェブサイトhttps://neumoratx.com/
企業コードNMRA
上場日Sep 15, 2023
最高経営責任者「CEO」Berns (Paul L)
Neumora Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
Mr. Alaa A. Halawa
Mr. Alaa A. Halawa
Independent Director
Independent Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. David Piacquad
Mr. David Piacquad
Independent Director
Independent Director
--
--
Ms. Helen Rubinstein
Ms. Helen Rubinstein
IR Contact Officer
IR Contact Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Paul L. Berns
Mr. Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
7.71M
+0.56%
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
47.72K
--
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Dr. Daljit Singh (Bill) Aurora, Pharm.D.
Chief Operating and Development Officer
Chief Operating and Development Officer
34.02K
-265.51%
Mr. Michael Lee Milligan
Mr. Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
21.03K
-6.83%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
20.10K
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
President
President
--
--
よくある質問
Neumora Therapeutics Incの上位5名の株主は誰ですか？
Neumora Therapeutics Incの上位5名の株主は以下のとおりです。Mr. Paul L. Berns
Neumora Therapeutics Inc（NMRA）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Neumora Therapeutics Incの株式を保有している機関は301社あり、保有株式の総市場価値は約106.55Mで、全体の57.52%を占めています。2025Q4と比較して、機関の持ち株は-16535931.00増加しています。